References
- Takahashi H, Yamamoto M, Suzuki C, Naishiro Y, Shinomura Y, Imai K. The birthday of a new syndrome: IgG4-related diseases constitute a clinical entity. Autoimmun Rev. 2010;9:591–4.
- Yamamoto M, Harada S, Ohara M, et al. Clinical and patho-logical differences between Mikulicz's disease and Sjogren's syndrome. Rheumatology (Oxford). 2005;44:227–34.
- Hamano H, Kawa S, Horiuchi A, et al. High serum IgG4 con-centrations in patients with sclerosing pancreatitis. N Engl J Med. 2001;344:732–8.
- Masalci Y, Dong L, Kurose N, et al. Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis. 2009;68:1310–5.
- Kamisawa T, Chen PY, Tu Y, et al. Pancreatic cancer with a high serum IgG4 concentration. World J Gastroenterol. 2006;12:6225–8.
- Fukui T, Mitsuyama T, Takaoka M, et al. Pancreatic cancer associated with autoimmune pancreatitis in remission. Intern Med. 2008;47:151–5.
- Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T, Japan Cancer Surveillance Research Group. Cancer incidence and incidence rates in Japan in 2003: based on data from 13 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) Project. Jpn J Clin Oncol. 2009;39: 850–8.
- Ghazale A, Chari S. Is autoimmune pancreatitis a risk factor for pancreatic cancer? Pancreas. 2007;35:376.
- Loss M, Esposito I, Hedderich DM, et al. Autoimmune pancre-atitis complicated by carcinoma of the pancreatobiliary system: a case report and review of the literature. Pancreas. 2011;40:151–4.
- Nakajo M, Jinnouchi S, Fukukura Y, Tanabe H, Tateno R, Nakajo M. The efficacy of whole-body FDG-PET or PET/CT for autoimmune pancreatitis and associated extrapancreatic autoim-mune lesions. Eur J Nucl Med Mol Imaging. 2007;34:2088–95.
- Nguyen VX, De Petris G, Nguyen BD. Usefulness of PET/CT imaging in systemic IgG4-related sclerosing disease. A report of three cases. JOP. 2011;12:297–305.
- Wilson CB. PET scanning in oncology. Eur J Cancer. 1992;28: 508–10.
- Masaki Y, Sugai S. Lymphoproliferative disorders in Sjögren's syndrome. Autoimmun Rev. 2004;3:175–82.
- Zhang W, Feng S, Yan S, Zhao Y, Li M, Sun J, et al. Incidence of malignancy in primary Sjögren's syndrome in Chinese cohort. Rheumatology (Oxford). 2010;49:571–7.
- Lazarus MN, Robinson D, Mak V, Moller H, Isenberg DA. Incidence of cancer in a cohort of patients with primary Sjögren's syndrome. Rheumatology (Oxford). 2006;45:1012–5.
- Kauppi M, Pukkala E, Isomäki H. Elevated incidence of hema-tologic malignancies in patients with Sjögren's syndrome com-pared with patients with rheumatoid arthritis (Finland). Cancer Causes Control. 1997;8:201–4.
- Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analy-sis. Arch Intern Med. 2005;165:2337–44.
- Takanishi N, Ghazale AH, Smyrk TC, Mandrekar JN, Chari ST. Possible association between IgG4-associated systemic disease with or without autoimmune pancreatitis and non-Hodgkin lym-phoma. Pancreas. 2009;38: 523–6.
- Sato Y, Notohara K, Kojima M, Takata K, Masaki Y, Yoshino T. IgG4-related disease: historical overview and pathology of hematological disorders. Pathol Int. 2010;60:247–58.
- Teng MW, Ngiow SF, von Scheidt B, McLaughlin N, Sparwasser T, Smyth MJ. Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth. Cancer Res. 2010;70:7800–9.
- Ghazale A, Chari ST, Smyrk TC, et al. Value of serum IgG4 in the diagnosis of autoimmune pancreatitis and in distinguishing it from pancreatic cancer. Am J Gastroenterol. 2007;102:1646–53.